XCNQ
CHGX
, Last price
CAD
Name
Chitogenx Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
ChitogenX Inc. is a biologics firm focused on orthopedic and sports medicine, committing its efforts to pioneering novel soft tissue repair technologies. The company's primary objective is to elevate the efficacy of sports medicine surgical procedures through its research and development. Its developmental pipeline includes a range of specialized products: Ortho-R, a specific formulation designed for rotator cuff injuries; Ortho-M, a biopolymer addressing meniscus repair; Ortho-C, another biopolymer for the regeneration of articular cartilage; and Ortho-V, a biopolymer developed to facilitate the healing of osteoarthritis. Additionally, they are advancing ORTHO-T, a biopolymer formulation engineered for tendon healing and regeneration. Previously known as Ortho Regenerative Technologies Inc., the company adopted its current name, ChitogenX Inc., in September of 2022. Established in 2015, ChitogenX maintains its headquarters in Kirkland, Canada.
Key people
Steven Saviuk
Executive Co-Chairman of the Board
Executive Co-Chairman of the Board, Acting Chief Executive Officer
Jeff Skinner
Vice President - Business Development
Benedek Simo
Corporate Controller · since 2018
Michael Daro Buschmann
Director
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑01 | 2023‑01 | 2022‑01 | 2021‑01 | 2020‑01 | 2019‑01 | 2018‑01 | 2017‑01 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||